RiverTree Advisors’s Gilead Sciences GILD Stock Holding History

RiverTree Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,505	Closed	-$215K	–	43
2022 Q4	$215K	Buy	+2,505	New	+$198K	0.18%	31

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RiverTree Advisors's GILD Position: Q1 2023 in Review

RiverTree Advisors sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 2,505 shares — an estimated $215K sold.

RiverTree Advisors first reported a position in GILD in Q4 2022 and held it in 1 quarter. The position peaked at $215K in Q4 2022. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

RiverTree Advisors reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
RiverTree Advisors sold 2,505 Gilead Sciences shares in Q1 2023, an estimated $215K.
RiverTree Advisors first reported a position in Gilead Sciences in Q4 2022 and held it in 1 quarter.
RiverTree Advisors's Gilead Sciences position peaked at $215K in Q4 2022.
1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on RiverTree Advisors's 13F filing for Q1 2023, filed 15 May 2023.